Evidence map›Paper›PMID 41552821›Full record

ArticleFrontiers in pharmacology2025

Jaranol: a compound with therapeutic activity against pathological cardiac remodelling via multi-target inhibition of the Snai3/TLR2 and NF-κB signaling pathways.

Yao Zhang, Nan Li, Shiqi Chu, Heqing Fu, Xiaowen Yang, Huimin Xia, Yunfeng Xiao, Zhibin Xiao, Jing Liu, Yu Dong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yao Zhang *Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Nan Li *Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Shiqi Chu *Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Heqing FuDepartment of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Xiaowen YangDepartment of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Huimin XiaDepartment of Natural Medicinal Chemistry, College of Pharmacy, Inner Mongolia Medical University, Hohhot, China.
Yunfeng XiaoCenter for New Drug Safety Evaluation and Research, Inner Mongolia Medical University, Hohhot, China.
Zhibin XiaoDepartment of Clinical Pharmacy, College of Pharmacy, Inner Mongolia Medical University, Hohhot, China.
Jing LiuDepartment of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Yu DongDepartment of Natural Medicinal Chemistry, College of Pharmacy, Inner Mongolia Medical University, Hohhot, China.
Tianlong LiuDepartment of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibiting pathological cardiac remodelling is considered an important therapeutic approach for heart failure, although effective strategies are still lacking in the clinic. Jaranol was found to be widely distributed in Chinese herbal medicine with multi biological functions, however, its effects on pathological cardiac remodelling remain unexplored. The present study identified the potential therapeutic effects of jaranol on cardiac remodelling base-joint analysis of the serum proteomic profile of patients with heart failure and

Indexed as

cardiac remodellingjaranolNF-κB signaling pathwaysprotective effectSnai3/TLR2 signaling pathways

Identifiers

PMID41552821
PMCPMC12807897

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.